Patents Assigned to ELLIPSES PHARMA LIMITED
  • Methods of treating cancer using compounds containing a vascular disrupting agent
    Patent number: 10912839
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 9, 2021
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds containing a vascular disrupting agent
    Patent number: 10556014
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 11, 2020
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby